Laron Syndrome is a rare genetic condition that affects how your body uses growth hormone. It's caused by a problem with the receptors that normally catch growth hormone. This means your body doesn't get the signal to grow properly, leading to short stature. It's not caused by a lack of growth hormone itself, but by the body's inability to respond to it.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Laron syndrome is a rare genetic condition in which the body cannot respond to growth hormone. The pituitary gland makes growth hormone normally, often in larger amounts than usual, but the receptor that should receive the hormone on the body's cells does not work. As a result, the body makes very little insulin-like growth factor 1 (IGF-1), the hormone that carries out much of growth hormone's work on bones, muscle and metabolism. Doctors also call it growth hormone insensitivity or primary IGF-1 deficiency. Babies are usually close to normal size at birth, then grow slowly from early childhood. Without treatment, adult men typically reach about 4.5 feet and women just over 4 feet. Other common features include a prominent forehead, a small face with a flattened nasal bridge, small hands and feet, reduced muscle strength, delayed puberty, thin hair and low blood sugar in infancy. Adults tend to gain body fat. Features vary, even between relatives with the same gene change. About 350 people worldwide have been diagnosed, and the largest known group lives in southern Ecuador.
Laron syndrome is caused by changes in the growth hormone receptor gene, which holds the instructions for building the receptor. It is present from birth and is not caused by anything a parent or child did. Most cases are inherited in an autosomal recessive pattern: a child is affected when they receive an altered copy of the gene from each parent. The parents are carriers who usually have no signs themselves. Because carriers are more common in certain communities, the condition clusters in particular families and regions. Much less often, a single altered copy passed down from an affected parent is enough to cause it.
The condition usually comes to attention because a child falls further and further below the growth curve. A pediatric endocrinologist, a specialist in children's hormones and growth, reviews growth records, family history and diet, and orders tests to rule out more common causes of short stature, such as poor nutrition, thyroid problems, celiac disease and kidney or liver disease. An X-ray of the hand and wrist (bone age) shows how much growing time remains. The pattern that points to Laron syndrome is a combination: very low IGF-1 in the blood, alongside normal or high growth hormone. In ordinary growth hormone deficiency, both are low. Doctors describe these results as standard deviation scores, which compare a child with others of the same age and sex. The US definition of severe primary IGF-1 deficiency requires both height and IGF-1 to be at least 3 standard deviations below average, meaning shorter and lower than roughly 99.9 percent of peers, with growth hormone that is not low. Genetic testing of the growth hormone receptor gene can confirm the diagnosis and helps relatives understand their own chances of being carriers.
Because the body cannot use growth hormone, growth hormone injections do not help. The approved treatment replaces the missing hormone further down the chain: mecasermin (Increlex) is a lab-made form of IGF-1, given as an injection under the skin twice a day. It is approved in the US for children 2 and older and is supervised by a pediatric endocrinologist, who starts at a low dose and raises it gradually. Mecasermin increases growth speed, and children grow more when treatment starts young, before other growth treatments and well before puberty. Even so, most people with Laron syndrome remain shorter than average as adults; in one international registry, only about 1 in 10 treated people with Laron syndrome reached an adult height in the normal range. Treatment stops once the growth plates close. Doctors who have followed people with Laron syndrome for decades report that early treatment can also prevent or improve some of the other effects of low IGF-1. The main day-to-day trade-off is low blood sugar, since IGF-1 acts partly like insulin, and children with Laron syndrome are more prone to it than others on this treatment. Each dose is given within about 20 minutes of a meal or snack and skipped if the child does not eat; missed doses are not made up. Blood sugar checks before meals are usual while the dose is being adjusted, and caregivers learn to recognize the signs. Regular visits also include eye exams and checks of the tonsils, hips and spine, because the drug can occasionally cause raised pressure around the brain, enlarged tonsils or adenoids, and hip or spine problems during fast growth. Care goes beyond height: attention to diet and weight, dental care, and support at school and in adapting everyday spaces all matter over a lifetime.
Laron syndrome is lifelong. For children on treatment, life involves a routine of twice-daily injections timed around meals, regular growth measurements and specialist visits every few months. Puberty often comes later than in peers. In adulthood, the main health concerns shift to body weight and metabolism. Adults tend to accumulate body fat, and a large Israeli group followed into adult life developed problems such as diabetes, fatty liver, heart disease and joint or nerve problems that affected work and daily life. Studies of the Ecuadorian group, by contrast, found much lower rates of type 2 diabetes and cancer than in unaffected relatives. Researchers are still working out why these findings differ, and life expectancy does not appear to be longer than average. In practice, ongoing care with attention to weight, blood sugar, the liver and the heart remains worthwhile. Very short stature also brings practical challenges, from reaching counters and driving to finding clothes and workplace accommodations. Patient organizations for rare growth conditions and for people of short stature can help families find peers and practical advice.
See a doctor if a child is growing noticeably more slowly than others or falling further below their growth curve, especially when relatives have had very short stature. Adults with Laron syndrome benefit from regular checks of weight, blood sugar, liver health and blood pressure. During mecasermin treatment, contact the care team promptly if low blood sugar keeps happening, with shakiness, sweating, irritability or confusion, even after a meal or snack. Also report new headaches with vomiting or vision changes, loud snoring or pauses in breathing during sleep, and a new limp or hip or knee pain. Call 911 if a child with Laron syndrome has a seizure, passes out or cannot be woken, which can be a sign of severe low blood sugar, or has trouble breathing or swelling of the face or throat after an injection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Laron Syndrome is like, what's helped you, or ask the community a question.